Ventyx Biosciences, Inc. Q2 FY2023 earnings call

Key Points

• Raju Mohan emphasized the company's focus on novel oral therapies for immune diseases, with ongoing Phase 2 trials for VTX958 (plaque psoriasis, Crohn's disease, psoriatic arthritis) and VTX002 (ulcerative colitis).
• Completed enrollment in Phase 2 SERENITY trial of VTX958 in moderate to severe plaque psoriasis, with top-line data expected in Q4 2023. Progress on extended release tablet for VTX958 towards Phase 3 trials in 2024.
• Completed enrollment in Phase 2 trial of VTX002 in moderate to severely active ulcerative colitis, with top-line results expected early in Q4 2023. Believes VTX002 may have differentiator efficacy vs. other ulcerative colitis drugs.
• NLRP3 inhibitor portfolio progress: VTX2735 in Phase 2 trials for CAPS patients, VTX3232 initiated in Phase 1 trial in healthy volunteers.
• Bill Sandborn provided details on VTX958 Phase 2 trials, enrollment progress, and upcoming data release. Discussed VTX002's Phase 2 trial in ulcerative colitis and NLRP3 inhibitor portfolio progress.

No specific product segment financial performance data provided in the transcript, as it does not detail absolute revenue and contribution % for each segment.

Guidance Points

• Anticipates top-line data from Phase 2 SERENITY trial (psoriasis) and VTX002 trial (ulcerative colitis) in Q4 2023.
• Plans to have an optimized once daily tablet for VTX958 ready for Phase 3 trials in 2024.
• Cash, cash equivalents, and marketable securities of $332.3M as of June 30, 2023, sufficient to support operations into 2025.

Risks

• Forward-looking statements are subject to risks and uncertainties outlined in Ventyx's most recent periodic reports filed with the SEC. No specific operational failures or detailed risk discussions beyond general forward-looking statement disclosures.

Q: Michael Yee asked about TYK2 results in psoriasis and read-through to Crohn's.

A: Bill Sandborn discussed aiming for PASI 75, 90, 100 levels seen with other agents, and how PD data for IL-23 relates to Crohn's confidence.

Q: Alex Thompson asked about QD formulation delay and discontinuation rates.

A: Raju Mohan said ample buffer for QD formulation, no impact on Phase 3; Bill Sandborn noted discontinuation rates don't affect statistical power in analyses.

Q: Vikram Purohit asked about Sotyktu's commercial impact and cash runway.

A: Marty Auster discussed Sotyktu's commercial progress and cash sufficient for planned operations into 2025.

Q: Unidentified Analyst asked about PASI score reflection and Phase 3 prep for VTX958 and VTX002.

A: Raju Mohan said Phase 3 prep activities are on track; Bill Sandborn discussed PASI 75 as sensitive outcome measure.

Q: Derek Archila asked about VTX002 geographic diversity and VTX2735 data.

A: Bill Sandborn discussed geographic diversity in trials; Raju Mohan talked about VTX2735 and 3232 being Phase 2 ready.

Q: Chris Shibutani asked about psoriatic arthritis trial read-through and Crohn's enrollment.

A: Bill Sandborn discussed expectations for psoriatic arthritis trial; Bill Sandborn noted Crohn's enrollment on track.

Q: Emily Bodnar asked about psoriatic arthritis bar and TYK2 in other indications.

A: Bill Sandborn talked about internal bar for psoriatic arthritis; discussed potential of TYK2 in other indications like alopecia and lupus.

Q: Sam Slutsky asked about Zeposia launch factors and next-gen S1P1.

A: Bill Sandborn and Marty Auster discussed Zeposia launch factors and differentiators for next-gen S1P1 drugs